ACADIA Pharmaceuticals Inc. (ACAD)

NMS – Real Time Price. Currency in USD

29.74

+0.33 (1.12%)

Market open: Aug 12, 2026, 12:25 PM EDT

29.99

+0.58 (1.97%)

Previous after-hours: Aug 11, 2026, 7:39 PM EDT

Stock details

Previous close: 29.41$
Day's range: 29.1 - 29.76$
52-week range: 19.69 - 29.76$
Volume: 1 346 523
Average volume: 2 182 924
Beta: 1.3
EPS (TTM): 2.25
PE ratio (TTM): 13.25
Forward P/E: 48.14
Market cap: 5 067 505 066
Shares outstanding: 172 305 511
Dividend yield: N/A
Next earnings date: 2026-11-11
Sector: Healthcare
Industry: Biotechnology

About the company

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripepti... read more

CEO: Catherine Owen Adams
Country: United States
IPO Date: 2004-05-27
Employees: 798
Fiscal Year End: January - December
Website: https://www.acadia.com

Revenue Breakdown

Innovative Medicines / 100.00%

News

No Data

There are no news for this stock.

Chart: ACAD

Loading Chart...

Overall Score

6 / 1060%

Octagon View

Strength & Weakness

Company's cash reserves $385.0M significantly exceed its total debt $73.9M, ensuring strong financial flexibility

Total current assets $1.2B exceed Total current liabilities $361.4M, highlighting excellent liquidity

Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management

The company has no interest-bearing debt, showcasing excellent financial strength

The company generates positive free cash flow $95.7M, supporting its financial health

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	3.39	6.05	10
Quick ratio	3.30	5.63	10
Debt to Equity	0.06	0.30	9.0
Debt to Assets	0.04	1.04	9.0
Interest coverage	N/A	-16.91	10
Weighted average score			9.6

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	517M	726M	958M	1.07B	1.14B
Gross Profit	507M	681M	861M	972M	1.04B
Operating Income	-224M	-73M	84M	105M	86M
Net Income	-216M	-61M	226M	391M	380M
EBITDA	-222M	-68M	100M	117M	98M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	90.81	-11.73	10
Operating margin %	12.29	-24.60	6.0
Net margin %	10.23	-172.20	8.0
EBITDA margin %	13.31	-201.27	5.0
Cash flow margin %	32.73	-156.39	10
Weighted average score			7.8

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	26.03	-57.97	10
ROE	36.98	-63.56	10
ROIC	35.32	-42.57	10
ROCE	1.85	-71.10	4.0
Weighted average score			8.5

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	18.7	-54.64	5.0
Next quarter	26.95	-86.42	5.5
Current year	18.07	-74.86	5.0
Next year	12.98	56.85	9.0
Weighted average score			6.1

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	14.88	766.1	800	232.62	9.5
Y/Y	16.4	18.13	12.5	50.32	8.8
3y average	28.06	204.59	203.03	308.5	10
5y average	20.12	125.1	124.56	189.47	10
Weighted average score					9.6

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	13.18	-5.25	7.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	4.45	64.66	6.4
P/B	3.88	2.96	3.6
Weighted average score			4.5

DCF Model

DCF Model Period5 years

Discount rate8.79%

Perpetual growth rate3%

Revenue 5 year CAGR15.95%

FCF 5 year CAGR4

Fair value15.3$

Stock price29.46$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$15.3

UndervaluedStock priceOvervalued

$29.46

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Catherine Owen Adams

Country

United States

IPO Date

2004-05-27

Employees

798

Fiscal Year End

January - December

Website

https://www.acadia.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

3.39

6.05

Quick ratio

3.30

5.63

Debt to Equity

0.06

0.30

9.0

Debt to Assets

0.04

1.04

9.0

Interest coverage

N/A

-16.91

Weighted average score

9.6

METRIC

2022

2023

2024

2025

TTM

Total Revenue

517M

726M

958M

1.07B

1.14B

Gross Profit

507M

681M

861M

972M

1.04B

Operating Income

-224M

-73M

84M

105M

86M

Net Income

-216M

-61M

226M

391M

380M

EBITDA

-222M

-68M

100M

117M

98M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

90.81

-11.73

Operating margin %

12.29

-24.60

6.0

Net margin %

10.23

-172.20

8.0

EBITDA margin %

13.31

-201.27

5.0

Cash flow margin %

32.73

-156.39

Weighted average score

7.8

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

26.03

-57.97

ROE

36.98

-63.56

ROIC

35.32

-42.57

ROCE

1.85

-71.10

4.0

Weighted average score

8.5

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

18.7

-54.64

5.0

Next quarter

26.95

-86.42

5.5

Current year

18.07

-74.86

5.0

Next year

12.98

56.85

9.0

Weighted average score

6.1

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

14.88

766.1

800

232.62

9.5

Y/Y

16.4

18.13

12.5

50.32

8.8

3y average

28.06

204.59

203.03

308.5

5y average

20.12

125.1

124.56

189.47

Weighted average score

9.6

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

13.18

-5.25

7.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

4.45

64.66

6.4

P/B

3.88

2.96

3.6

Weighted average score

4.5

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

ACADIA Pharmaceuticals Inc. (ACAD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ACADIA Pharmaceuticals Inc. (ACAD)

Stock details

About the company

Revenue Breakdown

News

Chart: ACAD

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$15.3

$29.46

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: ACAD

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$15.3

$29.46

Economic Moat